JSSH(000518)2024-08-30 08:59Financial Performance - The company's operating revenue for the reporting period was ¥105,808,385.29, a decrease of 12.85% compared to ¥121,411,354.73 in the same period last year[11]. - The net profit attributable to shareholders was -¥11,058,090.16, showing an improvement of 70.73% from -¥37,775,397.48 in the previous year[11]. - The net cash flow from operating activities was -¥82,819.54, a decline of 110.25% compared to ¥808,121.15 in the same period last year[11]. - The basic earnings per share were -¥0.0107, reflecting a 70.84% improvement from -¥0.0367 in the previous year[11]. - The pharmaceutical segment contributed ¥103,630,023.59, accounting for 97.94% of total revenue, with a year-on-year decrease of 9.96%[22]. - The gross profit margin for the pharmaceutical segment was 67.23%, down 6.93% from the previous year[22]. - The company reported a significant reduction in sales expenses, which were ¥35,319,052.80, down 46.33% from ¥65,807,996.66 in the previous year[20]. - The company reported a net loss of CNY 632,950,086.55 in retained earnings, compared to a loss of CNY 621,891,996.39 previously, indicating a worsening financial position[71]. - The company reported a comprehensive income total of -37.78 million yuan for the current period, indicating a challenging financial environment[89]. Assets and Liabilities - Total assets at the end of the reporting period were ¥648,501,210.76, a decrease of 1.89% from ¥660,975,034.49 at the end of the previous year[11]. - The net assets attributable to shareholders were ¥470,648,864.53, down 2.30% from ¥481,706,954.69 at the end of the previous year[11]. - The company's cash and cash equivalents decreased by ¥7,889,067.91, a decline of 26.54% compared to the previous year[20]. - The total current assets decreased from ¥509,380,002.54 to ¥505,712,427.80, a decline of about 0.3%[69]. - Total liabilities decreased from CNY 148,194,542.06 to CNY 147,363,744.72, a decline of about 0.6%[71]. - The company's equity attributable to shareholders decreased from CNY 481,706,954.69 to CNY 470,648,864.53, a decline of approximately 2.2%[71]. - The total liabilities decreased to CNY 106,598,176.47 from CNY 107,622,580.44, indicating a reduction of 0.95%[76]. Cash Flow - Cash flow from operating activities showed a net outflow of CNY 82,819.54, a significant decline from a net inflow of CNY 808,121.15 in the first half of 2023[80]. - The company’s cash and cash equivalents decreased from ¥18,927,001.92 to ¥11,037,934.01, representing a decline of approximately 41.5%[69]. - Cash and cash equivalents at the end of the first half of 2024 were CNY 11.04 million, down from CNY 21.37 million at the end of the first half of 2023[81]. - The total cash and cash equivalents at the end of the period amounted to ¥11,037,934.01, a decrease from ¥18,927,001.92 at the beginning of the period, reflecting a decline of approximately 41.0%[190]. Research and Development - Research and development expenses were ¥14,278,997.48, a slight decrease of 1.39% from ¥14,480,935.62 in the previous year[20]. - The company has not disclosed any significant new product developments or market expansion strategies in this report[2]. - The company has initiated research and development efforts for new technologies, aiming to enhance its product offerings in the future[89]. Corporate Governance and Compliance - The company has established a comprehensive corporate governance structure to protect the interests of minority shareholders and ensure compliance with relevant laws and regulations[39]. - The company emphasizes timely, truthful, and accurate information disclosure to enhance transparency and protect the rights of all shareholders[39]. - The company has not engaged in any major related party transactions during the reporting period, indicating a focus on operational integrity[45]. - The company has not reported any changes in share capital or share repurchase activities during the reporting period[59]. - The company is committed to complying with national environmental protection laws and standards[33]. Environmental Compliance - The company is subject to strict environmental regulations and holds a valid pollution discharge permit until July 14, 2027[33]. - The wastewater treatment plant operates with a biochemical method and has a processing capacity of 120 tons per day, established in December 2021, with stable and compliant discharge[38]. - The company has a stable operation of air pollution control facilities with a total capacity of 10,500 m³/h, established in 2020 and 2005[37]. - The company has no administrative penalties related to environmental issues during the reporting period[38]. Market Position and Strategy - The company primarily engages in the production and sales of biopharmaceutical products, including recombinant human interleukin-2 and recombinant human granulocyte colony-stimulating factor, which are used for cancer treatment[15]. - The company has a market presence in the biopharmaceutical sector, recognized for its high-quality products such as EPO injection and interleukin-2 injection[18]. - The company plans to accelerate the disposal and turnover of its seedling inventory through collaboration with local governments on large-scale landscaping projects[28]. - The company is exploring strategic partnerships and potential acquisitions to strengthen its market position moving forward[89]. Employee and Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 100,964, with major shareholders holding significant stakes, including 14.32% by Yu Qinfeng and 14.00% by Wang Hongming[59]. - The company has no current employee stock ownership plans or other incentive measures in place[32]. Financial Instruments and Accounting Policies - The company recognizes expected liabilities when there is a present obligation that is likely to result in an outflow of economic benefits[167]. - Revenue is recognized when control of the goods is transferred to the customer, considering various conditions such as contract approval and payment terms[169]. - The company recognizes lease liabilities at the present value of unpaid lease payments, excluding short-term leases and low-value asset leases[178]. - The company measures the fair value of assets and liabilities based on market participant assumptions, using observable inputs whenever possible[182].